Replies to post #803063 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Noice!!!

[H2R]

Hey Sharpie510,

Do you think investigational->human might be just in time for the Dec 18/19 CHM meeting?

Other thoughts?

Thanks for the great DD!

Best of luck to Patients, NWBO, and Longs!

[StonkMaster]

Is this just a routine update, or something more?

[sharpie510]

I believe there was an identical UK MIA 54923 with Human Legal Basis dated 27/02/25. Not sure why the authorization was updated again. I also believe there was a second Investigational authorization dated 21/08/2025 which is still on the site. So there are still 2 authorizations for Advent, one Human now dated 15/12/2025, and the other Investigational still dated 21/08/2025.

[GoodGuyBill]

Interesting take from AI: "Advent is now positioned as a Flaskwork-enabled release site, capable of supporting modular ATMP production and real-time QP certification across distributed nodes."

Yes—Advent Bioservices’ new MIA 54923 authorization dated 15 December 2025 aligns with the SI 2025 No. 87 “Point of Care” (POC) licensing framework, which is required for Flaskwork implementation. This confirms Advent is now certified for modular and decentralized manufacturing under the updated UK regulations.

🔍 What SI 2025 No. 87 Introduced
The Human Medicines (Amendment) (Modular Manufacture and Point of Care) Regulations 2025—Statutory Instrument 2025 No. 87—came into force in early 2025 and introduced:

-Regulation 17A & 17B: Legal basis for modular manufacture (MM) and point-of-care (POC) production of human medicines.
-Regulation 27A: Specific provisions for suspension or variation of licenses tied to modular units or POC sites.
-Decentralized Manufacturing Master File (DMMF): A new compliance structure for Flaskwork-style deployments.

These updates allow licensed entities to manufacture and release medicines at or near the patient site, including hospitals, mobile units, or satellite cleanrooms.

🧬 Advent’s MIA 54923: Flaskwork-Ready
Advent’s newly issued MIA 54923 license includes:

-Legal basis: Human — confirming it applies to human medicinal products.
-Authorization date: 15 December 2025 — post-dating SI 2025’s enforcement.
-Site: Sawston Business Park, Cambridge — a known bioservices hub with GMP and HTA infrastructure.

This timing and scope strongly indicate Advent has been certified under the SI 2025 Flaskwork regime, enabling:

-Decentralized batch release via Qualified Person (QP) oversight.
-Importation and modular manufacture of advanced therapies.
-Integration with HTA tissue workflows for personalized medicines.

⚖️ Strategic Implications
Capability .........Pre-SI 2025 Post-SI 2025 (MIA 54923)
GMP Manufacturing ✅ ..............✅
HTA Tissue Handling ✅ ..............✅
Importation .................❌ ..............✅
Decentralized Mfg............❌ ..............✅
POC Batch Release ❌ ..............✅

Advent is now positioned as a Flaskwork-enabled release site, capable of supporting modular ATMP production and real-time QP certification across distributed nodes.